Factors influencing choice of b/ts DMARDs in managing inflammatory arthritis from a patient perspective: a systematic review of global evidence and a patient-based survey from Hong Kong

Li, Yihua; Lau, Lauren K W; Peng, Kuan; Zhang, Dexing; Dong, Dong; Wong, Ian C K; Li, Xue

doi:10.1136/bmjopen-2022-069681

Cited by 1 publication

(2 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[5][6][7][8] A major barrier preventing the use of bDMARDs is the substantial drug cost associated with them. 9 The cost-effectiveness of bDMARDs, indicating the trade-off between increased medication expenditure and the additional health benefit, is vital for public formulary enlisting and reimbursement decisions. Many studies have attempted to elucidate whether initiating bDMARDs after the failure of methotrexate is cost-effective compared with csDMARDs, where the conclusions were controversial and highly sensitive to the price of bDMARDs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis

Peng,

Chan,

Wang

et al. 2024

JAMA Netw Open

Self Cite

View full text Add to dashboard Cite

ImportanceAmong patients with rheumatoid arthritis (RA) who had an inadequate response to methotrexate, a treatment sequence initiated with biosimilar disease-modifying antirheumatic drugs (DMARDs) provides better clinical efficacy compared with conventional synthetic DMARDs recommended by current treatment guidelines; but its cost-effectiveness evidence remains unclear.ObjectiveTo evaluate the cost-effectiveness of the treatment sequence initiated with biosimilar DMARDs after failure with methotrexate vs leflunomide and inform formulary listing decisions.Design, Setting, and ParticipantsThis economic evaluation’s cost-effectiveness analysis was performed at a Hong Kong public institution using the Markov disease transition model to simulate the lifetime disease progression and cost for patients with RA, using monetary value in 2022. Scenario and sensitivity analyses were performed to test the internal validity of the modeling conclusion. Participants included patients diagnosed with RA from 2000 to 2021 who were retrieved retrospectively from local electronic medical records to generate model input parameters. Statistical analysis was performed from January 2023 to March 2024.InterventionsThe model assesses 3 competing treatment sequences initiated with biosimilar infliximab (CT-P13), biosimilar adalimumab (ABP-501), and leflunomide; all used in combination with methotrexate.Main Outcomes and MeasuresLifetime health care cost and quality-adjusted life-years (QALYs) of the simulated cohort.ResultsIn total, 25 099 patients with RA were identified (mean [SD] age, 56 [17] years; 19 469 [72.7%] women). In the base-case analysis, the lifetime health care cost and QALYs for the treatment sequence initiated with leflunomide were US $154 632 and 14.82 QALYs, respectively; for biosimilar infliximab, they were US $152 326 and 15.35 QALYs, respectively; and for biosimilar adalimumab, they were US $145 419 and 15.55 QALYs, respectively. Both biosimilar sequences presented lower costs and greater QALYs than the leflunomide sequence. In the deterministic sensitivity analysis, the incremental cost-effectiveness ratio (US$/QALY) comparing biosimilar infliximab sequence vs leflunomide sequence and biosimilar adalimumab sequence vs leflunomide sequence ranged from −15 797 to −8615 and −9088 to 10 238, respectively, all below the predefined willingness-to-pay threshold (US $48 555/QALY gain). In the probabilistic sensitivity analysis, the probability of treatment sequence initiated with leflunomide, biosimilar infliximab, and biosmilar adalimumab being cost-effective out of 10 000 iterations was 0%, 9%, and 91%, respectively.Conclusions and RelevanceIn this economic evaluation study, the treatment sequences initiated with biosimilar DMARDs were cost-effective compared with the treatment sequence initiated with leflunomide in managing patients with RA who experienced failure with the initial methotrexate treatment. These results suggest the need to update clinical treatment guidelines for initiating biosimilars immediately after the failure of methotrexate for patients with RA.

show abstract

Section: Introductionmentioning

confidence: 99%

“…A major barrier preventing the use of bDMARDs is the substantial drug cost associated with them . The cost-effectiveness of bDMARDs, indicating the trade-off between increased medication expenditure and the additional health benefit, is vital for public formulary enlisting and reimbursement decisions.…”

Section: Introductionmentioning

confidence: 99%